Axiom Biosciences, known for regenerative and genetic medicine innovation, is making an unusual move for a US biotech company by planning its primary public offering in Hong Kong in 2027, aiming to tap into Asia’s growing biotech investment ecosystem before listing in the US two years later.
- Axiom selects Hong Kong as primary listing venue for 2027 IPO.
- Hong Kong biotech market outperforms Nasdaq and US indices since 2025.
- Secondary US listing planned for 2029 to access broader institutional pool.
What happened
Axiom Biosciences, a San Diego-based biotechnology firm focused on regenerative and genetic medicines, announced plans to conduct its primary initial public offering (IPO) in Hong Kong in 2027. This approach is notable because many Chinese biotech firms traditionally list in the US, while purely American firms rarely choose Hong Kong as their first public listing location.
Following the Hong Kong IPO, Axiom intends to pursue a secondary listing in the United States by 2029. The company aims to leverage Hong Kong’s increasing prominence as a biotech fundraising hub and its proximity to Asian clinical and commercial partners, while still accessing the deep capital pools and broad institutional investor base available in the US market.
Why it matters
Hong Kong has emerged as a leading global biotech capital market, bolstered by regulatory reforms in 2025 that streamlined IPO processes and attracted international biotech firms. Since 2018, 86 companies have raised over $17.8 billion in Hong Kong, with the Hang Seng Biotech Index surging more than 75% from its 2025 low—outperforming key US biotech indexes during the same period.
This trend indicates growing investor sophistication and a mature biotech ecosystem in Hong Kong. For American biotech companies like Axiom, listing there offers access to specialized biotech investors and potential partnerships within Asia’s expanding pharmaceutical industry, while also capitalizing on market conditions that provide attractive valuations relative to the US Nasdaq market.
What to watch next
Investors and industry watchers should monitor the progress of Axiom’s Hong Kong IPO preparation and how it influences other American biotech firms’ listing strategies. The move could signal a shift toward greater integration of Western biotech companies with Asian capital markets and clinical networks.
Attention will also focus on Axiom’s ability to attract Asian institutional and biotech-focused investors, as well as the performance of its shares post-IPO in comparison to its future US secondary listing, which will test the appetite of global institutional investors and validate Hong Kong’s position as an alternative principal listing venue for biotech firms.